The FDA Dropped Menopause Hormone Therapy's Black Box Warning: What Changed

For more than twenty years, a box of bold text on a prescription label shaped how millions of women thought about menopause. That box is being taken down, and the story behind it is worth understanding.

If you or someone close to you reached menopause in the last two decades, you may have a memory of the conversation. A symptom that was wrecking sleep, a doctor who sounded reluctant, a sense that hormone therapy was something to be endured without, if at all. The reluctance had a source, and the source has now been revisited.

This is general information, not medical advice. Decisions about hormones are individual, and the sections at the end are meant to help you prepare for a conversation with a clinician, not to replace one.

Why the warning existed

In 2002, the Women's Health Initiative, a very large US trial, stopped its estrogen-plus-progestin arm early after finding increased rates of breast cancer, heart disease, stroke and blood clots in the women taking the combination. The headlines were immediate and severe. Prescriptions fell sharply, and boxed warnings, the strongest label warning the FDA uses, were added to hormone products.

The trial was real and the findings were real. What took years to sink in was who had been studied. The average participant was in her early sixties, and most were well over ten years past menopause. They were not the women who typically seek treatment for hot flushes and night sweats, who are in their late forties and early fifties.

The timing hypothesis

When researchers went back and split the data by age and by years since menopause, a pattern appeared. For women who started within about ten years of menopause, or who were under sixty, the balance of risks looked different, and in some analyses the cardiovascular picture looked neutral or favourable. For women who started much later, the risks were more concerning.

This is called the timing hypothesis. The idea, loosely, is that estrogen interacts differently with blood vessels that are still healthy than with vessels that have already accumulated years of damage. It remains a hypothesis in the sense that it was not what the original trial was designed to test, but it has shaped most guidance since.

The practical consequence is large. The same drug can have a different risk-benefit profile depending on when it is started. A blanket warning cannot express that, which is much of why the blanket warnings were eventually reconsidered.

What the guidance now says

The FDA has moved to remove the broad boxed warnings from menopause hormone therapy products. As I understand the announcement, a narrower warning about the uterine lining with estrogen-alone products remains, so the current label for any specific product is worth reading.

Professional bodies have been moving the same way. NICE in the UK (April 2026), the International Menopause Society (December 2025) and the European Society of Endocrinology (October 2025) have each issued updated guidance describing menopause hormone therapy as safe and effective for vasomotor symptoms and for preventing osteoporosis in women under sixty or within ten years of menopause.

What the Danish study actually measured

Much of the recent conversation cites the Danish Osteoporosis Prevention Study, usually shortened to DOPS. It is worth being exact about what it was.

Roughly a thousand recently menopausal women in Denmark were randomly assigned either to hormone therapy (estradiol, with a progestogen for women who had a uterus) or to no treatment, starting around 1990. Treatment ran for about ten years, and the women were followed afterwards. Its original focus was bone, which is why it carries that name.

The finding that has attracted attention is about the heart. Women who started estradiol around age fifty had about half the risk of the combined outcome of death, heart attack or heart failure, and the difference was still visible after sixteen years of follow-up.

What it cannot tell us

I do not want to oversell this, and neither did the researchers. There are real limits.

Size. A thousand women is a small trial for heart outcomes. Events were few, so the estimates are less certain than the headline suggests.
No placebo. The trial was open-label, meaning participants and clinicians knew who was taking treatment. That can influence behaviour and reporting.
Not the original aim. Cardiovascular events were a later and secondary look, not the main question the study was built to answer.
Population. The women were Danish, mostly healthy and mostly recently menopausal. Results may not carry over to everyone.

So the honest summary is: a long, careful, randomised study that points in a reassuring direction, within the age window where guidance already said hormone therapy is reasonable. It supports the timing hypothesis. It does not prove it.

Why the name changed

You may have noticed that clinicians now say menopause hormone therapy, or MHT, rather than hormone replacement therapy. This is not only fashion.

"Replacement" implied that menopause is a deficiency to be corrected indefinitely, and that treatment should continue as long as a woman lives. "Therapy" describes what it actually is: a treatment chosen for particular symptoms or goals, for a period, and reviewed. That framing makes a shorter, more deliberate conversation possible, and it makes stopping a normal option instead of a failure.

Who still should not use it

Hormone therapy is not for everyone, and removing a warning does not remove those cautions. It is generally not recommended, or is approached very carefully, in people with:

a history of breast cancer or another hormone-sensitive cancer;
unexplained vaginal bleeding that has not been investigated;
active liver disease;
a history of blood clots or stroke, or high risk of them;
known significant cardiovascular disease, which needs individual assessment.

Those with other conditions are often still candidates, and the form of treatment matters. Skin patches and gels may carry a lower clot risk than tablets, and low-dose vaginal estrogen for local symptoms is a separate conversation altogether.

Where you might sit: a rough decision guide

This is a map, not a verdict. Your own history and preferences will move you on it.

Under sixty, or within ten years of your last period, with bothersome symptoms. This is the group the updated guidance speaks to most directly. Hormone therapy is generally considered a reasonable option, and the question becomes which type, dose and route.
Under sixty, within ten years, with mild or no symptoms but concern about bones. Therapy can prevent bone loss, but other options exist. Weigh them with a clinician instead of defaulting to either.
Over sixty, or more than ten years after menopause, considering starting. The risk-benefit balance is less favourable for starting, and the decision is individual. It is not an automatic no, but it deserves more careful discussion.
Already taking it and doing well. There is no universal age at which you must stop. A periodic review of the reason, dose and alternatives is the sensible habit.
Any of the cautions above apply. Start with the specialist who knows your history before changing anything.

What to ask your doctor

A short script can make the appointment easier. You might say something like:

"My symptoms are affecting [sleep, work, mood]. I'd like to talk about whether hormone therapy is an option for me."
"I'm [age] and my last period was [about when]. How does the current guidance apply to that?"
"What is my personal risk with my family history and my own history?"
"If we try it, which form and dose would you start with, and when would we review it?"
"What are the alternatives if hormones are not right for me?"

FAQ

Does removing the black box mean hormone therapy is now risk-free?

No. It means the broad warning has been judged too blunt for the evidence. Real risks remain for some people, and the age at which treatment starts still matters.

Is this the same as the "hormone replacement" my mother took?

Partly. Many modern products use different forms and routes, and the thinking about who benefits has changed. Your mother's experience may have been shaped by older prescribing patterns.

How long can someone take it?

There is no fixed rule. The usual approach is the lowest effective dose for as long as it is helping, with regular review of whether it still should continue.

Do I have to take hormones to treat menopause symptoms?

No. There are non-hormonal options for hot flushes and sleep, and lifestyle changes help some people. Hormone therapy is one option, not an obligation.

The change on the label is small and the change in the conversation may be large. It is worth asking the question again, even if you asked it once and left with a no.